Loading...
OTCM
QTXB
Market cap118kUSD
Apr 08, Last price  
0.00USD
Name

Quantrx Biomedical Corp

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
44,42966,36455,64591,463747,119624,4952,551,2691,493,67719,08515,2366,1132,4301560000000
Net income
0k
P
-46,405-19,842-1,092,558-7,692,514-6,044,337-7,721,401-3,153,496831,188-783,616-717,967-358,331-826,985-467,780-397,994869,139-736,850-820,101-469,454-476,7010
CFO
0k
P
-11,580-71,187-1,022,334-1,817,560-4,985,904-2,801,308-1,116,199-1,833,722-427,379-182,101-149,532-291,911-226,378-94,643-150,613-257,920-191,673-74,923-49,4780

Profile

QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.
URL
IPO date
May 31, 1988
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
(4)
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT